XML 57 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Sale of Significant Ownership Interest in AgeX to Juvenescence Limited (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Nov. 02, 2018
Aug. 30, 2018
Jun. 30, 2019
Jun. 30, 2019
Nov. 28, 2018
Debt instrument maturity date       Aug. 30, 2020  
Parent Company [Member] | Common Stock [Member]          
Number of shares owned         1,700,000
Common stock shares issued and outstanding percentage         4.80%
Juvenescence Limited [Member]          
Number of share sold   14,400,000      
Stock Purchase Agreement [Member] | Juvenescence Limited [Member]          
Number of share sold   14,400,000      
Sale of stock price per share   $ 3.00      
Purchase price of shares   $ 43,200      
Purchase price amount paid $ 10,800        
Indemnity cap   $ 4,300      
Debt instrument interest rate   7.00%      
Proceeds from public offering   $ 50,000      
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Series A Preferred Share [Member]          
Debt conversion, price per share   $ 15.60      
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Promissory Note [Member]          
Purchase price amount paid   $ 21,600      
Debt instrument interest rate   7.00%      
Debt instrument maturity date   Aug. 30, 2020      
Interest income debt     $ 378 $ 756  
Promissory Note principal and accrued interest     $ 22,900 $ 22,900  
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Closing of Transaction [Member]          
Purchase price amount paid   $ 10,800      
Shareholder Agreement [Member]          
Shareholder agreement description   BioTime and Juvenescence entered into a Shareholder Agreement, dated August 30, 2018, setting forth the governance, approval and voting rights of the parties with respect to their holdings of AgeX common stock, including rights of representation on the AgeX Board of Directors, approval rights, preemptive rights, rights of first refusal and co-sale and drag-along and tag-along rights for so long as either BioTime or Juvenescence continue to own at least 15% of the outstanding shares of AgeX common stock.